<DOC>
	<DOCNO>NCT00268892</DOCNO>
	<brief_summary>The purpose extension study collect long-term safety tolerability information support marketing authorisation application three-month dosage regimen degarelix .</brief_summary>
	<brief_title>Extension Study Investigating Long-Term Safety Degarelix Three-Month Depots Patients With Prostate Cancer</brief_title>
	<detailed_description>The data include data participant participate main study FE200486 CS15 ( NCT00113753 ) extension study FE200486 CS15A .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has give write consent prior studyrelated activity perform . A studyrelated activity define procedure would perform normal management patient . Has successfully complete main study . Exclusion Criterion : Has withdrawn main study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>